DHCNL — Diversified Healthcare Trust

Summary of DHCNL Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $379.6 million for Q4 2025.
• Adjusted EBITDAre: $72.4 million.
• Normalized FFO: $21.8 million, or $0.09 per share.
• Consolidated NOI Growth: 31.3% year-over-year.
• SHOP NOI: Increased 27.6% year-over-year to $38.3 million for Q4; full-year SHOP NOI reached $139.3 million, at the high end of guidance.
• Occupancy Rates: Same-property occupancy increased 90 basis points year-over-year to 82.4%.
• Leverage: Net debt to adjusted EBITDA improved from 11.2x at year-end 2024 to 8.1x at the end of 2025.

2. Strategic Updates and Business Highlights

• Completed over $1.4 billion in capital markets activity, including asset sales and financing.
• Transitioned 116 communities from AlerisLife to seven operators, enhancing operational efficiency.
• Renovated over 30 communities, focusing on improving property-specific business plans.
• Implemented advanced CRM platforms and dynamic pricing strategies to boost occupancy and revenue.
• Significant focus on repositioning underutilized areas within communities, potentially adding 500 SHOP units with a mid-teens ROI.

3. Forward Guidance and Outlook

• 2026 Guidance:
  • SHOP NOI expected between $175 million and $185 million.
  • Medical Office and Life Science NOI projected at $94 million to $98 million.
  • Adjusted EBITDAre anticipated between $290 million and $305 million.
  • Normalized FFO forecasted at $0.52 to $0.58 per share.
• The company expects continued growth in occupancy and revenue, with a focus on operational improvements and disciplined capital spending.

4. Bad News, Challenges, or Points of Concern

• The transition of properties has created operational noise, although this is expected to stabilize as new operators integrate.
• A decline in Medical Office and Life Science NOI is anticipated due to the sale of properties contributing $12.3 million in 2025.
• The company has identified potential challenges in renewing leases for some Medical Office and Life Science properties, with two significant tenants expected to vacate.
• The need for ongoing operational adjustments as new operators take over could impact short-term performance.

5. Notable Q&A Insights

• Management emphasized a focus on organic growth through operational improvements rather than external acquisitions, although they remain open to future opportunities.
• The cadence of NOI growth is expected to be back-loaded in 2026, with significant contributions anticipated in the second and third quarters.
• The company does not currently prioritize dividend adjustments despite anticipated growth in NOI and FFO, indicating a focus on operational stability and strategic initiatives.
• Management noted that while January showed promising trends, the full impact of recent transitions would take time to materialize, suggesting a cautious but optimistic outlook for the upcoming quarters.

Overall, DHCNL demonstrated strong performance in 2025, with significant strategic initiatives underway to enhance operational efficiency and drive future growth, despite some challenges related to property transitions and market conditions.